Возраст домена | 11 лет |
Дата окончания | Истек срок регистрации |
ИКС | 10 |
Страниц в Google | 7170 |
Страниц в Яндексе | n/a |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 312817 |
Alexa Country | 85871 |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
Biotech and Pharma Industry News | BioPharma Dive
n/a
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
UTF-8
159.93 КБ
1 264
9 564 симв.
8 020 симв.
Данные предоставлены сервисом semrush
Идет сбор информации... Обновить
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 16 Мая 2016 ) | |
Количество ссылок на сайт | 432 |
Количество доменов, которые ссылаются на сайт | 163 |
Количество найденных анкоров | 127 |
Исходящие (внешние) ссылки домена | 1554 |
Количество доменов, на которые ссылается сайт | 148 |
Количество исходящих анкоров | 320 |
Внешние ссылки главной страницы ( 19 ) | |
biopharmadive.schoolkeep.com/ | Online Courses |
industrydive.com/privacy-policy/ | privacy policy |
biopharmadive.schoolkeep.com/catalog/i0dtnhfo/beyond-the-sci... | Beyond the Science: The Business of Drug Development |
biopharmadive.schoolkeep.com/catalog/d7xtet6r/lecture-1-the-... | The Drug Discovery and Development Process |
biopharmadive.schoolkeep.com/catalog/6r5ddjsp/lecture-2-phar... | Pharmacoeconomics, Pharmaceutical Pricing, Pushback and Policy |
biopharmadive.schoolkeep.com/catalog/21l3818i/lecture-3-inte... | Intellectual Property |
bloomberg.com/news/articles/2020-01-09/23andme-licenses-drug... | 23andMe Licenses Drug Compound to Spanish Drugmaker Almirall |
reuters.com/article/us-blackstone-group-fund/blackstone-rais... | Blackstone raises three-quarters of targeted $4.6 billion life sciences fund |
healthcaredive.com/news/the-government-recovered-3b-in-fraud... | The government recovered $3B in fraud last year. Nearly 90% was from healthcare |
industrydive.com/article-reprints/ | Article Reprints |
healthcaredive.com | Healthcare Dive |
medtechdive.com | MedTech Dive |
twitter.com/BioPharmaDive | <img> |
facebook.com/biopharmadive/ | <img> |
linkedin.com/company/biopharma-dive-biotech-and-pharma-news | <img> |
industrydive.com | Industry Dive |
industrydive.com/industries/ | other publications |
industrydive.com/terms-of-use/ | Terms of use |
industrydive.com/takedown-policy/ | Take down policy |
Внутренние ссылки главной страницы ( 63 ) | |
/ | Home |
/deep-dive/ | Deep Dive |
/opinion/ | Opinion |
/library/ | Library |
/events/ | Events |
/signup/ | Newsletter |
/topic/pharma/ | Pharma |
/topic/biotech/ | Biotech |
/topic/fda/ | FDA |
/topic/clinical-trials/ | Clinical Trials |
/topic/deals/ | Deals |
/topic/drug-pricing/ | Drug Pricing |
/topic/gene-therapy/ | Gene Therapy |
/news/biotech-trends-2020/569957/ | Read more ➔ |
/news/lilly-buy-dermira-challenge-dupixent/570220/ | Lilly to buy Dermira, challenging Sanofi and Regeneron's Dupixent |
/news/blueprint-Ayvakit-FDA-approval-GIST-cancer/570223/ | Blueprint wins 1st FDA approval with targeted cancer drug |
/news/moderna-cmv-vaccine-prepare-market/570143/ | Moderna, though early in development, prepares its vaccine for market |
/news/ultragenyx-gene-therapy-data-boosts-shares/570221/ | Ultragenyx boosted by trial data for 2nd gene therapy |
/news/solid-cuts-one-third-of-staff-goes-all-in-on-delayed-g... | Solid cuts one-third of staff, goes all in on delayed gene therapy |
/news/5-trends-to-watch-at-the-fda-in-2020/570077/ | 5 trends to watch at the FDA in 2020 |
/news/amag-restructuring-ceo-william-heiden-exit-vyleesi-sal... | Amag CEO to step down as troubled pharma looks to sell 2 drugs |
/topic/marketing/ | Marketing |
/news/abbvie-allergan-botox-subsidiary/570036/ | AbbVie to house Allergan Botox business in separate unit |
/news/us-cancer-death-rate-drops-by-most-on-record/570039/ | US cancer death rate drops by most on record |
/news/blueprint-submit-pralsetinib-ret-lung-cancer-lilly/570... | Lilly looms over Blueprint as the biotech files targeted cancer drug |
/news/gsks-hiv-two-drug-strategy-challenges-gilead/569852/ | GSK's plan to take over the HIV drug market hasn't worked out |
/news/apellis-alexion-soliris-pegcetacoplan-pnh/569941/ | Alexion's blockbuster Soliris bested by Apellis in Phase 3 trial |
/news/merck-keytruda-small-cell-lung-cancer-fall-short-rival... | Merck's Keytruda falls short of rivals in 1 lung cancer type |
/news/merck-adds-to-lung-cancer-wall-with-otsuka-deal/569843... | Merck adds to lung cancer wall with Otsuka deal |
/news/bavencio-bladder-cancer-positive-data-pfizer-merck-kga... | Pfizer, Merck KGaA show immunotherapy's survival benefit in bladder cancer |
/news/incyte-trial-setback-itacitinib-gvhd-gravitas/569763/ | Trial failure keeps Incyte searching for its next act |
/news/2020-drug-price-increases-pfizer-abbvie-gilead/569679/ | Pfizer, AbbVie and Gilead among drugmakers boosting prices to start 2020 |
/news/illumina-pacbio-acquisition-terminated-ftc-pushback/56... | Illumina scraps $1.2B PacBio takeover amid regulatory pushback |
/news/wave-huntington-drug-data-roche-ionis/569682/ | Wave's Huntington's drug shows effect but falls short of mark set by Roche and Ionis |
/news/5-fda-approval-decisions-to-watch-first-quarter/569687... | 5 FDA approval decisions to watch in the 1st quarter |
/news/lynparza-pancreatic-fda-approval-astrazeneca-merck/569... | AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer |
/news/roche-sarepta-1-billion-dollar-gene-therapy-deal/56959... | Roche hands $1B to Sarepta in major return to gene therapy deals |
/news/intracellular-lumateperone-approval-Caplyta-neuroscien... | Intra-Cellular approval keeps focus on FDA's neuroscience review process |
/news/astrazeneca-daiichi-enhertu-fda-approve-breast-cancer/... | Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals |
/news/fda-rejects-crl-glaxosmithkline-viiv-hiv-drug/569596/ | FDA rejects GSK's HIV therapy in setback to two-drug strategy |
/news/fda-approves-merck-ebola-vaccine/569522/ | FDA approves Merck's Ebola vaccine, a historic first against deadly virus |
/news/biopharma-dive-awards-2019/565265/ | The BioPharma Dive Awards for 2019 |
/news/stealth-phase-3-setback-elamipretide-alexion/569521/ | Stealth's rare disease drug falls short in study, sinking shares |
/news/bladder-cancer-approval-gives-seattle-genetics-its-sec... | Bladder cancer approval gives Seattle Genetics its second drug |
/news/ionis-license-biogen-regain-rights-novartis/569437/ | Biogen, Novartis go different ways on Ionis therapies |
?page=2 | More stories |
/news/pharma-patents-march-in-rights-drug-pricing/568357/ | Will sky-high drug prices spur the US to use an obscure power over patents? |
/news/takeda-car-t-gene-therapy-research-andy-plump/567640/ | Takeda sees cell, gene therapy in its future. Is it too late? |
/news/pharmacquired/560761/ | Pharmacquired: A series on what's driving industry M&A |
/news/biopharma-bankruptcy-trends-2019-uptick-pharma-biotech... | Bankrupt biopharmas are rare. 2019 has some worried that's changing. |
/what-we-are-reading | View all |
/events/dia-regulatory-submissions-information-and-docum-nor... | DIA Regulatory Submissions, Information, and Document Management Forum |
/events/asia-pacific-healthcare-compliance-certificate-pro-s... | Asia-Pacific Healthcare Compliance Certificate Program |
/events/middle-east-healthcare-compliance-certificate-prog-d... | Middle East Healthcare Compliance Certificate Program |
/events/2020-pda-annual-meeting-raleigh-nc-mar-30-2020-bioph... | 2020 PDA Annual Meeting |
/submit-tip/ | Submit A Tip |
/editors/ | Editorial Team |
/about/ | About |
/press-release/ | Press Releases |
/what-we-are-reading/ | What We're Reading |
/advertise/ | Advertising |
/feedback/ | Contact |
biopharmadive.com/feeds/news/ | <img> |
Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.
Domain Name: BIOPHARMADIVE.COM
Registrar: ENOM, INC.
Sponsoring Registrar IANA ID: 48
Whois Server: whois.enom.com
Referral URL: http://www.enom.com
Name Server: IVY.NS.CLOUDFLARE.COM
Name Server: SID.NS.CLOUDFLARE.COM
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Updated Date: 23-apr-2016
Creation Date: 23-may-2013
Expiration Date: 23-may-2017
>>> Last update of whois database: Mon, 14 Nov 2016 22:23:50 GMT <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
Domain Name: BIOPHARMADIVE.COM
Registry Domain ID: 1803374573_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.enom.com
Registrar URL: www.enom.com
Updated Date: 2014-04-21T22:18:51.00Z
Creation Date: 2013-05-23T15:09:00.00Z
Registrar Registration Expiration Date: 2017-05-23T15:09:23.00Z
Registrar: ENOM, INC.
Registrar IANA ID: 48
Reseller: NAMECHEAP.COM
Domain Status: clientTransferProhibited https://www.icann.org/epp#clientTransferProhibited
Registry Registrant ID:
Registrant Name: SEAN GRIFFEY
Registrant Organization: INDUSTRY DIVE
Registrant Street: 829 7TH ST NW
Registrant Street: 3RD FLOOR
Registrant City: WASHINGTON
Registrant State/Province: DC
Registrant Postal Code: 20001
Registrant Country: US
Registrant Phone: +1.2026433483
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: INFO@INDUSTRYDIVE.COM
Registry Admin ID:
Admin Name: ELI DICKINSON
Admin Organization: INDUSTRY DIVE
Admin Street: 829 7TH ST NW
Admin Street: 3RD FLOOR
Admin City: WASHINGTON
Admin State/Province: DC
Admin Postal Code: 20001
Admin Country: US
Admin Phone: +1.2026433483
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: WEBMASTER@INDUSTRYDIVE.COM
Registry Tech ID:
Tech Name: ELI DICKINSON
Tech Organization: INDUSTRY DIVE
Tech Street: 829 7TH ST NW
Tech Street: 3RD FLOOR
Tech City: WASHINGTON
Tech State/Province: DC
Tech Postal Code: 20001
Tech Country: US
Tech Phone: +1.2026433483
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: WEBMASTER@INDUSTRYDIVE.COM
Name Server: IVY.NS.CLOUDFLARE.COM
Name Server: SID.NS.CLOUDFLARE.COM
Registrar Abuse Contact Email: abuse@enom.com
Registrar Abuse Contact Phone: +1.4252982646
>>> Last update of WHOIS database: 2014-04-21T22:18:51.00Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
#
# ..;coxkOOOOOOkxoc;'.
# .:d0NWMMMMMMMMMMMMMMWN0xc'
# .:kXMMMMMMMMMMMMMMMMMMMMMMMXl.
# .c0WMMMMMMMMMMMMMMMMMMMMMMMXd'
# ,OWMMMMMMMMMMMMMMMMMMMMMMMXo' ..
# cXMMMMMMXo::::::::::::::col. .lKXl.
# lNMMMMMMM0' .lKWMMNo
# :XMMMMMMMM0' .l0WMMMMMNc
# .OMMMMMMMMM0' .ccccccc;. ,KMMMMMMMMO.
# :NMMMMMMMMM0' oWMMMMMMWKc. oWMMMMMMMN:
# lWMMMMMMMMM0' oWMMMMMMMMX: ,KMMMMMMMMo
# oMMMMMMMMMM0' oWMMMMMMMMNc ,KMMMMMMMMd
# cNMMMMMMMMM0' oWMMMMMMMNd. lWMMMMMMMWl
# '0MMMMMMMMWk. ,oooooooc' ,0MMMMMMMMK,
# oWMMMMMMXo. ,0MMMMMMMMWo
# .xWMMMXd' ,dXMMMMMMMMWk.
# .xWNx' .',''''''',,;coONMMMMMMMMMWk.
# .:, .l0WWWWWWWWWWWMMMMMMMMMMMMMNd.
# .lKWMMMMMMMMMMMMMMMMMMMMMMMWk;
# .lKWMMMMMMMMMMMMMMMMMMMMMMMNk;.
# .ckXWMMMMMMMMMMMMMMMMMMWXkl'
# .;ldO0XNWWWWWWNXKOxl;.
# ..'',,,,''..
#
#
# NOTE: Allow is a non-standard directive for robots.txt. It is allowed by Google bots. See https://developers.google.com/search/reference/robots_txt#allow
User-agent: *
Disallow: /admin/
Disallow: /trending/tweet/
Disallow: /newsletter/
Disallow: /healthcheck/
Disallow: /subpage/
Disallow: /ckeditor/
Disallow: /feeds/search/
Disallow: /jobs/edit/
Disallow: /wishfeedback/
Disallow: /api/
Disallow: /static/images/
# no deep queries to search
Disallow: /search/*
Allow: /search/$
# don't index our dynamic images
Disallow: /user_media/
Allow: /google_news_sitemap.xml
# hide old-school trend report
Disallow: /news/*/541893/
#
# Rules for specific crawlers below. Note these replace and override the '*' rules above.
#
# Allow Twitter to see all links
User-agent: Twitterbot
Disallow:
# Allow Googlebot-News to see header images and favicons, BUT make it follow all the directives from our * group
# See below link for why we have to repeat these directives
# https://developers.google.com/search/reference/robots_txt#order-of-precedence-for-user-agents
User-agent: Googlebot-News
Disallow: /admin/
Disallow: /trending/tweet/
Disallow: /newsletter/
Disallow: /healthcheck/
Disallow: /subpage/
Disallow: /ckeditor/
Disallow: /feeds/search/
Disallow: /jobs/edit/
Disallow: /wishfeedback/
Disallow: /api/
Disallow: /static/images/
# no deep queries to search
Disallow: /search/*
Allow: /search/$
Allow: /google_news_sitemap.xml
# hide old-school trend report
Disallow: /news/*/541893/
# Allow Google News to see header images and favicons
Allow: /user_media
Allow: /static/images/favicons
# Don't let Google Images crawler see anything at all
User-agent: Googlebot-Image
Disallow: /
# All Facebook crawler user-agent to see all
User-agent: facebookexternalhit/1.1
Disallow:
# Allow swiftbot custom search to see all, but with a delay
User-agent: Swiftbot
Disallow:
Crawl-delay: 2
104.24.2.17
104.24.3.17
CloudFlare
CloudFlare
HTTP/1.1 200 OK
Date: Sun, 12 Jan 2020 01:50:10 GMT
Content-Type: text/html; charset=utf-8
Transfer-Encoding: chunked
Connection: keep-alive
Set-Cookie: __cfduid=d85fb1b986dadf41f5307ea75bd06bd671578793810; expires=Tue, 11-Feb-20 01:50:10 GMT; path=/; domain=.biopharmadive.com; HttpOnly; SameSite=Lax; Secure
Vary: Cookie
Sniply-Options: BLOCK
Expires: Sun, 12 Jan 2020 01:50:23 GMT
Cache-Control: max-age=120
X-Location: NonEU
Accept-Ranges: bytes
X-Varnish: 1655543468 1655540514
Age: 107
Via: 1.1 varnish
X-Backend-Healthy: true
CF-Cache-Status: DYNAMIC
Expect-CT: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
Server: cloudflare
CF-RAY: 553b7a630e8ac17a-IAD
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"